| Dr Erika Renee Alberty, PHARMD | |
|
12266 Depaul Dr, Suite 105, Bridgeton, MO 63044 | |
| (314) 344-7300 | |
| Not Available |
| Full Name | Dr Erika Renee Alberty |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 12266 Depaul Dr, Bridgeton, Missouri |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336592757 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 2012026481 (Missouri) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Erika Renee Alberty, PHARMD 12266 Depaul Dr, Suite 105, Bridgeton, MO 63044 Ph: (314) 344-7300 | Dr Erika Renee Alberty, PHARMD 12266 Depaul Dr, Suite 105, Bridgeton, MO 63044 Ph: (314) 344-7300 |
News Archive
Screening large "libraries" of compounds to find those with a desired biological activity is a powerful method for discovering new drugs, but requires a large, expensive and dedicated facility. Now, scientists at the Florida campus of The Scripps Research Institute have devised the central component of a screening system that would be orders of magnitude smaller and cheaper.
Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company primarily focused on the pediatric market, today announced the acquisition of 100% of the outstanding membership interest in Macoven Pharmaceuticals, L.L.C. for approximately $2.2 million (which includes inventory of approximately $1.2 million), its entry into a $10 million credit facility with Regions Bank and the repurchase of 2,000,000 shares of its common stock from one of its employees in a privately negotiated transaction.
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, together with its international commercialization partners, today announced that enrollment has been initiated and the first patient has been randomized in a Phase 2b clinical trial called TRAVERSE.
A team of neuroscientists has discovered important new information in the search for an effective treatment for Alzheimer's disease, the debilitating neurological disorder that afflicts more than 5.3 million Americans and is the sixth-leading cause of death in the United States. Hey-Kyoung Lee, associate professor in the University of Maryland Department of Biology, and her research team have shown that they may be able to eliminate debilitating side effects caused by a promising Alzheimer's drug by stimulating the brain's nicotine receptors.
› Verified 3 days ago
Matthew Kahle, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 12345 Saint Charles Rock Rd, Bridgeton, MO 63044 Phone: 314-770-2479 | |
Jenny Lynne Kasen, PHARM D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 12921 Enterprise Way, Bridgeton, MO 63044 Phone: 314-344-9604 | |
Karl A Snyder, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 12921 Enterprise Way, Bridgeton, MO 63044 Phone: 314-344-9604 | |
Carolyn Hager, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 12345 Saint Charles Rock Rd, Bridgeton, MO 63044 Phone: 314-770-2479 | |
Ronald Savetz, BS Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 12345 Saint Charles Rock Rd, Bridgeton, MO 63044 Phone: 314-770-2479 | |
Michelle Spond, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 12921 Enterprise Way, Bridgeton, MO 63044 Phone: 314-344-9604 | |
Dr. Amanda Christine Baebler, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 11978 Saint Charles Rock Rd, Bridgeton, MO 63044 Phone: 314-291-2290 |